VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects aged 18 to 80 years old                   │ Subjects aged 18 to 80 years old                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous diagnosis of type 2 diabetes, fulfilling  │ Previous diagnosis of type 2 diabetes, fulfilling  │     100 │
│ at least one of the following criteria: 1) current │ at least one of the following criteria: 1) current │         │
│ treatment with oral antidiabetic drugs and/or      │ treatment with oral antidiabetic drugs and/or      │         │
│ insulin; 2) a fasting glucose value above 126      │ insulin; 2) a fasting glucose value above 126      │         │
│ mg/dl on at least 2 occasions; 3) blood glucose    │ mg/dl on at least 2 occasions; 3) blood glucose    │         │
│ level at 2 hours after an oral glucose tolerance   │ level at 2 hours after an oral glucose tolerance   │         │
│ test is equal to or more than 200 mg/dl; or 4) a   │ test is equal to or more than 200 mg/dl; or 4) a   │         │
│ glycated hemoglobin (HbA1c) level \> 6.5 %         │ glycated hemoglobin (HbA1c) level > 6.5 %          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical diagnosis of diabetic nephropathy, with a │ Clinical diagnosis of diabetic nephropathy, with a │     100 │
│ urinary albumin/creatinine ratio \>30 mg/g and an  │ urinary albumin/creatinine ratio >30 mg/g and an   │         │
│ estimated glomerular filtration rate more than 20  │ estimated glomerular filtration rate more than 20  │         │
│ ml/min per 1.73 m2                                 │ ml/min per 1.73 m2                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with stable doses of angiotensin-        │ Treatment with stable doses of angiotensin-        │     100 │
│ converting enzyme inhibitors, angiotensin II       │ converting enzyme inhibitors, angiotensin II       │         │
│ receptor blockers or anti-aldosterone agents in    │ receptor blockers or anti-aldosterone agents in    │         │
│ the last four weeks                                │ the last four weeks                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non diabetic nephropathy (confirmed by biopsy)     │ Non diabetic nephropathy (confirmed by biopsy)     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Dialysis for acute renal failure within the 6      │ Dialysis for acute renal failure within the 6      │     100 │
│ previous months                                    │ previous months                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Urinary albumin/creatinine ratio higher than 3000  │ Urinary albumin/creatinine ratio higher than 3000  │     100 │
│ mg/g, at the baseline visit                        │ mg/g, at the baseline visit                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stroke, transient ischemic attack, acute coronary  │ Stroke, transient ischemic attack, acute coronary  │     100 │
│ syndrome, or hospitalization for heart failure     │ syndrome, or hospitalization for heart failure     │         │
│ worsening, within the previous 30 days             │ worsening, within the previous 30 days             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Professional drivers, risk profession or           │ Professional drivers, risk profession or           │     100 │
│ respiratory failure                                │ respiratory failure                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant treatment with high doses of           │ Concomitant treatment with high doses of           │     100 │
│ acetylsalicylic acid (\> 500 mg/day) or continuous │ acetylsalicylic acid (> 500 mg/day) or continuous  │         │
│ treatment with non-steroidal anti-inflammatory     │ treatment with non-steroidal anti-inflammatory     │         │
│ drugs                                              │ drugs                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous treatment with CPAP                       │ Previous treatment with CPAP                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial within the │ Participation in another clinical trial within the │     100 │
│ 30 days prior to randomization                     │ 30 days prior to randomization                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Overweight or obesity (BMI ≥25 kg/m2)              │ Overweight or obesity (BMI =25 kg/m2)              │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic blood pressure ≥ 180 mmHg or diastolic    │ Systolic blood pressure = 180 mmHg or diastolic    │      98 │
│ blood pressure ≥ 110 mm Hg at the baseline visit   │ blood pressure = 110 mm Hg at the baseline visit   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence in the clinic history of relevant         │ Evidence in the clinic history of relevant         │      99 │
│ bilateral stenosis of renal artery (\> 75%)        │ bilateral stenosis of renal artery (> 75%)         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe daytime sleepiness (Epworth sleepiness      │ Severe daytime sleepiness (Epworth sleepiness      │      99 │
│ scale \>18)                                        │ scale >18)                                         │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Subjects aged 18 to 80 years old │      46 │
├───────────────────────────────────┼──────────────────────────────────┼─────────┤
│ Must have maximum age of 80 Years │ Subjects aged 18 to 80 years old │      49 │
╘═══════════════════════════════════╧══════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 93.77777777777777
OverAll Ratio: 95.88888888888889
